# University of Washington: Phase 2 study closed enrollment, 16 enrolled (Anxiety, Depression)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | University of Washington |
| Sponsor type | Academic and hospital |
| Study | Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies |
| NCT ID | NCT07336238 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Anxiety; Depression; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm |
| Intervention types | behavioral, drug, other |
| Target enrollment | 16 |
| Site countries | United States |
| Posted | 2026-01-13 |
| Planned start | 2026-05-19 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-29 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07336238). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.